Osimertinib in Advanced Non–Small-Cell Lung Cancer
Автор: NEJM Group
Загружено: 2017-02-16
Просмотров: 45941
EGFR tyrosine kinase inhibitors are standard treatment for non small-cell lung cancer. Despite high tumor response rates, disease progresses in most patients after 9 to 13 months. Is there a way to lengthen progression-free survival? New research findings are summarized in this short video. Full study: http://nej.md/2gymJkj
Доступные форматы для скачивания:
Скачать видео mp4
-
Информация по загрузке: